The survival of bacteria within phagocytes, usually macrophages, after ingestion is often the basis for chronic clinical infections (33) . Persistent infections due to facultative intracellular organisms frequently occur in the lung, where alveolar macrophages (AM) are the predominant phagocytic cell. Optimal therapy for these pulmonary intracellular infections would include the use of antimicrobial agents which penetrate phagocytes and inactivate intracellular bacteria.
As an initial step in establishing the characteristics of drug and cell which determine antibiotic entry into AM, we recently studied the uptake and accumulation of 14 antimicrobial agents by normal rabbit AM (11) . The cells were incubated with clinically appropriate concentrations of radiolabeled antibiotics for 2 h, and antibiotic uptake was measured at intervals. Many drugs failed to penetrate the macrophages readily. In comparison with other tested antibiotics, ethambutol, erythromycin, erythromycin propionate, and clindamycin were impressively concentrated by rabbit AM (range of cellular/extracellular antibiotic concentration ratio [C/E], 7 to 50).
Clindamycin uptake by AM was especially rapid and massive.
The above studies employed lengthy cell-drug incubation periods, up to 120 min, before determination of the antibiotic accumulation by AM. Such assays of intracellular drug concentrations may reflect factors other than, and in addition to, transport of the antimicrobial agent into the cell. To clearly define plasma membrane transport, we have now evaluated the initial (i.e., the earliest) rates of uptake by AM upon exposure to clindamycin. By this means we can accurately measure entry or transport free of contributions from exit (efflux) or other processes (3). The following studies were designed to characterize the membrane transport of clindamycin in rabbit AM.
MATERIALS AND METHODS
Collection of rabbit AM. Cells were collected from the lower respiratory tract of New Zealand rabbits by saline lavage, as previously described (7, 17 Radiolabeled substances in various concentrations (as noted below) were added to the macrophage suspensions. The mixtures were incubated at 37°C in 95% air-5% CO2. At the appropriate times, 0.2-ml samples of the incubation mixture (containing 2 x 106 cells) were removed, and uptake of the radiolabeled material by AM was determined. As previously reported (11) , the uptake of radiolabeled drugs (requiring rapid separation of cells from the incubation mixture) was measured by means of a velocity gradient centrifugation technique with a miniature centrifuge (Microfuge B; Beckman Instruments, Inc., Fullerton, Calif.). The separation process was accomplished as follows. In a microcentrifuge tube, the top layer was composed of cells, culture medium, and radiolabeled drug, the middle layer consisted of silicone oil, and the bottom layer was formic acid. Cells in the top layer were centrifuged through the water-impermeable silicone oil into the formic acid, which dissolves the cells. The centrifuge tubes were then frozen at -50°C, and the frozen layers were separated by slicing the tubes with a razor. The lower portion contained the radiolabeled material that had been taken up by the cells, and the upper portion contained the material still in solution.
Intracellular volumes were determined by adding 3H20 to suspensions of AM, allowing equilibrium, and then separating the cells from extracellular fluid by velocity gradient centrifugation. With this information, cell-associated drug concentrations were calculated (based on micromoles of drug per intracellular volume of 2 x 106 cells) and then expressed as the ratio of cellular to extracellular drug concentration (C/E).
Kinetic analyses of the uptake of clindamycin and other drugs during the initial exposure of AM to these materials were performed (2, 3, 29) . A double-reciprocal (Lineweaver-Burk) plot of uptake velocity versus drug concentration data was constructed from experiments with widely varying concentrations of radiolabeled drug. This plot allows calculation of the apparent binding affinity (Kin) and maximum velocity of transport (Vmax) for the transport system.
Characterization of clindamycin uptake. Additional studies were performed to define the mechanism of clindamycin transport by AM. The effects of environmental temperature and cell viability on antibiotic transport were determined. In addition, the influence of metabolic inhibitors and potential competitive inhibitors of clindamycin uptake was examined.
The following metabolic inhibitors were used: sodium cyanide (Sigma Chemical Co., St. Louis, Mo.), potassium fluoride (Mallinckrodt Inc., St. Louis, Mo.), iodoacetimide (Sigma), 2,4-dinitrophenol (Matheson Scientific, Inc., Rutherford, N.J.), and ouabain (Sigma). The concentrations of these substances are listed below. Cells in Hanks balanced salt solution with and without an inhibitor were incubated for 30 min at 37°C. Radiolabeled clindamycin was then added, and transport was measured as described above.
Other substances were evaluated for possible competitive inhibition of clindamycin uptake by AM. These materials included: nucleosides (adenosine, puromycin dihydrochloride; Sigma); 2-deoxy-D-glucose (Sigma), D-glucose (BBL Microbiology Systems, Cockeysville, Md.), and L-amino acids (glycine, leucine, lysine monohydrochloride, proline, methionine, serine, glutamic acid; Pierce Co., Rockford, Ill.). These materials were either preincubated for 30 min with AM or added to the cells at the same time as clindamycin. The uptake of radiolabeled clindamycin was measured as described above.
In some experiments, the possible inhibitory effect of unlabeled clindamycin on membrane transport of radiolabeled nucleosides, hexose, and amino acids in AM was examined.
RESULTS
Kinetic analysis of dindamycin transport in AM. An analysis of clindamycin uptake by AM during the first 45 s of exposure to the drug is shown in Fig. 1 . The Lineweaver-Burk plot depicts uptake velocity versus clindamycin concentration data. Clindamycin uptake obeys saturation kinetics, which is characteristic of a carrier-mediated transport system (11) . The clindamycin transport system is characterized by a high binding affinity (Km = 1 mM) and a high maximum velocity or rate of uptake (Vmax = 15.8 nmol/45 s per 10 cells).
Energy requirements of clindamycin transport. The energy requirements for the initial uptake of clindamycin by AM were determined. Antibiotic transport was dependent upon cell viability and "physiological" environmental temperature.
Thus, optimal uptake occurred only in live cells at 37°C. Formalin-killed AM rapidly bound clindamycin initially, but no additional uptake occurred with continued incubation (Fig. 2) .
Various inhibitors of cellular metabolism were evaluated for their influence on drug entry into AM (Fig. 3) . Potassium fluoride, an inhibitor of glycolysis, had no effect on clindamycin transport. Transport of the drug was decreased in the presence of sodium cyanide, which blocks mitochondrial oxidative metabolism. A classic uncoupler of oxidative phosphorylation, 2-4-dinitrophenol, also inhibited clindamycin uptake. Ouabain, an inhibitor of the cell membrane sodium-and potassium-transporting ATPase system (12, 21) also depressed clindamycin uptake.
Identification of the clindamycin transport system. Macrophages are known to have specific carrier-mediated transport systems for hexoses, amino acids, and nucleosides (3, 34) . The possibility that one of these systems might transport clindamycin was evaluated. Potential competitive inhibitors of clindamycin uptake (i.e., representative substances from each of the chemical groups given above) were preincubated with AM before the determination of radiolabeled clindamycin uptake. Clindamycin transport was not significantly altered in the presence of excess amino acids or hexose. In contrast, two nucleosides, adenosine and puromycin, had an inhibi- tory effect on early uptake of clindamycin by AM (Fig. 4) . Transport of the drug was depressed in the presence of 1 mM concentrations of these nucleosides.
The results of experiments defining the mechanism by which puromycin inhibits clindamycin transport are shown in Fig. 5 observed puromycin-induced alteration in clindamycin transport was documented by two observations: (i) cycloheximide, which inhibited macrophage protein synthesis as efficiently as puromycin did during the preincubation period, had no effect on clindamycin transport, and (ii) depression of protein synthesis by puromycin, which required a period of incubation with the macrophages, was not needed for the inhibition of clindamycin transport, as was observed even when both drugs were added to the cells simultaneously and clindamycin transport was measured immediately.
The kinetic analysis of clindamycin uptake in the presence and absence of puromycin during the first 2 min of exposure of AM to the antibiotic is shown in Fig. 6 . The Lineweaver-Burk plot confirms that the depressed uptake of clindamycin by puromycin is characteristic of competitive inhibiton, i.e., an increased Km (decreased binding affinity) and an unaltered Vmax for clindamycin transport (12) .
If clindamycin uptake by AM is mediated via the nucleoside transport system, then cellular handling of the normal substrate should be impeded in the presence of the antibiotic. Therefore, we evaluated the effect of clindamycin on the uptake of radiolabeled adenosine. Clindamycin did inhibit adenosine transport (Fig. 7) . The features of this process were characteristic of competitive inhibition (as noted above). As was expected, clindamycin (1 mM) had no effect on 2.
1. tion (33) . Bacteria with these characteristics include Mycobacterium tuberculosis, Listeria, Brucella, and some strains of Salmonella and Staphylococcus aureus. Optimal therapy of these infections would entail the use of antibiotics which can penetrate phagocytes and inactivate intracellular organisms. Unfortunately, most antibiotics lack one or both of these prop-3H-Adenosine Clindomycin,0.48mM (2) (8, 9, 13, 15, 16, 19) . In a recent study (11), we found that several antibiotics (ethambutol, erythromycin, and clindamycin) are selectively concentrated by AM. Accumulation of these specific drugs was shown to be an active, energy-requiring process. The natural substrate(s) for the uptake system(s) by which these antibiotics entered AM was not identified.
As clindamycin was more avidly accumulated by AM than any other of the antibiotics tested, we decided to examine the uptake of this drug in detail. In the present study, we evaluated the plasma membrane transport of the antibiotic. Determination of the initial rates of uptake by AM upon exposure to clindamycin allowed accurate measurement of entry or transport, without contributions from exit, metabolism, or intracellular sequestration of the drug.
Membrane transport of clindamycin in AM is an active process, with requirements for cellular viability, elevated environmental temperature, metabolic energy (which is dependent upon mitochondrial oxidative respiration and membrane Na-K pump activity), and establishment of a 40-to 50-fold cellular/extracellular gradient. Kinetic analysis of clindamycin transport revealed that the system exhibits saturation kinetics and has a high Km and a high Vmax.
Three plasma membrane transport systems for nonelectrolytes have been described in macrophages. These phagocytes are known to have specific carrier-mediated transport systems for hexoses, amino acids, and nucleosides (2, 3, 5, 6, 18, [24] [25] [26] [28] [29] [30] [31] . The possibility that one of these systems might transport clindamycin was evaluated in detail. We found that clindamycin uptake was not significantly altered in the presence of excess amino acids or hexose. However, adenosine and puromycin did depress uptake of the antibiotic in AM. Further evaluation revealed that decreased clindamycin uptake in the presence of puromycin was typical of competitive inhibition (increased Km without a change in Vmax). Conversely, competitive inhibition of adenosine transport by clindamycin was demonstrated.
Thus, clindamycin is transported into AM by means of the nucleoside system. The chemical or structural characteristics of clindamycin which allow the antibiotic to share the nucleoside transport system are uncertain. However, these substances do have similar ring components in their molecular structure. Whether other antibiotics actively accumulated by AM (e.g., erythromycin) are also transported by the nucleoside system remains to be determined. The biological consequences of clindamycin and other antibiotic transport in AM are under investigation.
